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Splice variant PRKC-z-PrC is a novel biomarker of human
prostate cancer
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P Smith1, MI Malki1, Y Ke1, CS Cooper3, C Gosden1 and CS Foster*,1
1Division of Pathology, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, 6th Floor, Duncan Building, Daulby Street,
Liverpool L69 3GA, UK; 2School of Biological Sciences, University of Liverpool, Liverpool L69 7ZB, UK; 3University of East Anglia, Norwich Research Park,
Norwich NR4 7TJ, UK
BACKGROUND: Previously, using gene-knockdown techniques together with genome expression array analysis, we showed the gene
protein Kinase C (PKC)-zeta (PRKCZ) to mediate the malignant phenotype of human prostate cancer. However, according to NCBI,
the gene has undergone several major iterations. Therefore, to understand the relationship between its structure and biological
activities, we have analysed its expressed sequence in prostate cancer cell lines and tissues.
METHODS: Transcriptome-walking and targeted PCR were used to sequence the mRNA transcribed from PRKCZ. Hydropathy
analysis was employed to analyse the hypothetical protein sequence subsequently translated and to identify an appropriate epitope to
generate a specific monoclonal antibody.
RESULTS: A novel sequence was identified within the 30-terminal domain of human PRKCZ that, in prostate cancer cell lines and tissues,
is expressed during transcription and thereafter translated into protein (designated PKC-z-PrC) independent of conventional PKC-z-a.
The monoclonal antibody detected expression of this 96 kD protein only within malignant prostatic epithelium.
INTERPRETATION: Transcription and translation of this gene sequence, including previous intronic sequences, generates a novel specific
biomarker of human prostate cancer. The presence of catalytic domains characteristic of classic PKC-b and atypical PKC-i within
PKC-z-PrC provides a potential mechanism for this PRKCZ variant to modulate the malignant prostatic phenotype out-with normal
cell-regulatory control.
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Previously, we have shown expression of the gene protein kinase C
(PKC)-zeta (PRKCZ) to be characteristic of human prostate cancer
(Cornford et al, 1999) where intensity of the protein PKC-z-a
detected immunohistochemically is predictive of aggressive pro-
static malignancy (Po0.001). RNAi gene knockdown, in vitro and
in vivo behavioural studies and gene expression array analysis
confirmed PRKCZ to be functionally involved in promoting the
malignant prostatic phenotype (Yao et al, 2010). The gene PRKCZ
is located on human chromosome 1 (at 1p36.33-p36.2) where it
covers 136.21 kb on the direct strand. Containing 104 exons,
it potentially encodes 46 structurally distinct splice variants
designated in AceView as a–u and va–vy. During the last decade,
the structure of human PRKCZ published by NCBI has undergone
several major revisions as novel data have accrued. Nevertheless,
important structure–function activities of the gene remain
incomplete. Presently, the structure of PRKCZ splice variant
‘a’ expressed in prostate cancer comprises 18 exons that are
transcribed to a 2295 bp mRNA and translated into 592
amino acids yielding a 67.7 kD protein (Supplementary Table 1).
Details of the current structural organisation of PRKCZ gene
variant ‘a’ is shown in Figure 1.
PKC isoenzymes are ancient proteins that appeared early during
prokaryote evolution (Kruse et al, 1996; Manning et al, 2002) and
are essential for the structural development and functional
maintenance of multi-cellular organisms (Suzuki et al, 2003).
Together, they comprise a complex family of some 14 serine–
threonine kinases characterised by fundamental similarities in the
structure of certain gene elements and in functional peptide
domains (Hanks et al, 1988; Kofler et al, 2002). Broadly considered
to be regulators of cellular homoeostasis and behavioural
phenotypes (Dempsey et al, 2000), these enzymes are increasingly
identified to be polyfunctional (Ohno and Nishizuka, 2002).
High homology between apparently different members within the
overall super family emphasises their common evolutionary
origins but can obscure their subtly different functions that are
crucial to understanding their roles in cancer cell survival and in
designing biologically appropriate therapeutic agents (Ali et al,
2009). The genes for all of these enzymes characteristically encode
multiple splice variants that are differentially expressed between
tissues during morphogenesis (Patel et al, 2006; Dobkin-Bekman
et al, 2010; Makary et al, 2011) and especially between malignant
tissues and their benign histogenic counterparts (Lee et al, 2010;
Urtreger et al, 2012).
PRKCZ expression profoundly affects cellular behaviour
(Le Good and Brindley, 2004; Xin et al, 2007), particularly in a
diverse range of malignancies (Liu et al, 2009; Wu et al, 2009)
where it modulates different biological mechanisms (Della Peruta
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et al, 2010; Luna-Ulloa et al, 2011; Valkov et al, 2011; Yu et al,
2011). Therefore, confirming its structure was considered as a
prerequisite for understanding the role of this gene in prostate
cancer. Thus, the aim of this study was to establish the detailed
organisation of the PRKCZ gene expressed in prostate cancer and
to test the hypothesis that alternative forms of PRKCZ might
contribute cellular properties distinct from conventional PKC-z-a,
hence promoting the malignant prostatic phenotype. We now
report the retention and transcription of a normally intronic
sequence within the 30-terminal region of PRKCZ together with its
translation into a novel protein (designated ‘PKC-z-PrC’) that have
been shown to be selective for human prostate cancer. This
sequence is expressed simultaneously, but independently, from
that of the conventional PKC-z-a. Inclusion of catalytic domains
characteristically expressed in classic PKC-b and atypical PKC-i-
provides evidence that anomalous variants of protein kinase (PK)
enzymes may promote the malignant phenotype of prostate cancer
cells by mechanisms out-with normal regulatory processes.
MATERIALS AND METHODS
Cell lines
Four human prostate epithelial cell lines PNT-2 (benign), LNCaP,
DU145 and PC-3M (highly malignant) were grown as monolayers
in RPMI 1640 (Invitrogen, Paisley, UK) supplemented with
10% (v/v) fetal calf serum (Invitrogen), penicillin (100 unitsml 1),
streptomycin (100 mgml 1) and L-glutamine (2mM). Additional
cell lines employed as the source of proteins for western blotting
included a non-malignant lung epithelial line (Beas-2b) together
with malignant cell lines from lung (COR-L88), bladder (HT1197),
pancreas (PANC) and breast (MCF-7). The culture media for the
stably-transfected prostatic epithelial cell line si-PRKC-z-a-PC-
3MT1-6, in which the gene PRKC-z-a had been knocked down using
si-RNA directed towards the unique 21 nt sequence – 50-GTGA
GAGACATGTGTCGTCTT-30 – contained within PRKCZ exon 1
(Yao et al, 2010), were also supplemented with 500 ng ml 1
Geneticin (Sigma, Gillingham, UK).
Human prostate tissues
Following informed consent from the patients, three human
radical prostatectomy specimens containing biopsy-proven pros-
tate cancers were obtained fresh. Following macroscopic inspec-
tion and dissection to provide diagnostic specimens, cores of tissue
(5mm diameter) were removed from several sites in the residual
material and submitted to frozen section examination to confirm
the composition of each specimen with respect to prostatic cancer
and non-malignant epithelium. Cores selected for further analysis
contained either entirely benign or entirely malignant epithelium
on microscopic analysis.
Ethical approval
The studies on human tissues were performed under the National
Research Ethics Service Licence 05/Q1505/76.
Rabbit polyclonal antiserum sc-216
Rabbit polyclonal antiserum sc-216, obtained commercially
from Santa Cruz Biotechnology (Insight Biotechnology Ltd,
Wembley, UK) was identical to that described in the original
immunohistochemical and western blotting studies (Cornford
et al, 1999; Yao et al, 2010) to reveal expression of PKC-z-a in
human prostate cancers. The peptide sequence recognised by
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Figure 1 (A) Full exonic sequence of NM variant ‘a’ (NCBI database Build 36, April 2011). Genome exon numbers are in square brackets. Sizes of
individual exons (blue boxes) and intervening introns are as shown. (B) Comparative structure of the 30-terminal region of PRKCZ NCBI database Build 36
(November 2011) between bases #124751 and #136201. Horizontal bars indicate the relative size and location of each exon. Preceding numbers (square
brackets and italics) denote the genome number assigned to each exon. Letters above each bar identify the splice variants that include the particular exon.
Numbers following each bar specify the length (bp) of each exon. Pink rectangles identify the size and location of individual coding regions. Yellow rectangles
denote the location of the gene sequence corresponding to the antigenic site identified by polyclonal antiserum sc-216. The upstream (50) extension
(253 bp) of exon 89 into the adjacent intronic region is identified in red.
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polyclonal antiserum sc-216 (Figure 2A) was released by Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Interrogation of the
protein structure revealed this sequence to correspond to a coding
sequence within exon 90 at the 50 terminus of the PRKCZ gene
(Figure 2B). Western blotting had previously confirmed this
protein to be strongly expressed in PC-3M cells.
Immunohistochemical staining
Histological sections of 12 paraffin wax-embedded prostate
cancers and 12 non-malignant prostate tissues from specimens
of benign prostatic disease without malignancy were obtained
from Department of Pathology, University of Liverpool, UK.
Conditions (dilution, temperature and pH) for staining with the
primary antibody were optimised using known standard positive
and negative tissues. Immunohistochemical staining was per-
formed using a fully automated Ventana Benchmark XT-TM
immunohistochemistry platform as specified previously (Foster
et al, 2009).
Quality control of mRNA and RT–PCR controls
For transcriptome-walking and subsequent sequencing studies, cell
lines were grown up and extracted in triplicate as separate
preparations to provide independent biological replicates. All
mRNA preparations were routinely measured using a Nanodrop
instrument (LabTech International, Ringmer, UK) to ensure
quality. Following each extraction, all preparations were treated
with DNase I to destroy any residual contamination by genomic
DNA. To exclude the possibility that the amplified PCR product
may be derived from genomic contamination, 1 mg total RNA was
amplified by PCR using the same primer pairs directly as a control
under the same conditions. Since the amount of genomic DNA in
total RNA is approximately  20 than that in the subsequently
purified mRNA, failure to amplify specific sequences from total
RNA, while generating a reliable product from corresponding
mRNA, is a reliable indicator of the latter’s purity. As negative
controls, a minus RT first-strand synthesis was performed to
ensure that the amplifications were derived from mRNA and not
from genomic DNA contamination. Additional negative controls
were obtained by PCR amplification of the cDNA and genomic
DNA using primers (Supplementary Table 2) to PRKCZ variants ‘f ’
and ‘n’ that were known from preliminary studies not to be
expressed by the prostatic cell lines used in this study. After
completion of the PCR reactions, amplified products were
separated by electrophoresis in agarose gels containing ethidium
bromide (0.5mgml 1). Bands were visualised under UV light,
eluted and submitted to sequence analysis.
RT–PCR to confirm expression of PRKC-z isoform
Total RNA was isolated from the five prostate cancer cell lines,
including the si-PRKC-z-a-PC-3MT1-6 knockdown cells, using
RNeasy Mini Kits (Qiagen, Crawley, UK), a ready-to-use reagent
for the isolation of total RNA from cells and tissues, following the
manufacturer’s recommendations. DNase I (Qiagen) was added to
the RNA sample to remove any traces of genomic DNA. Total RNA
was determined by Nanodrop. All RNA was assessed for quality
and purity using a BioAnalyzer (Agilent Technologies, Stockport,
UK) before being used in further studies. Only RNA with an RIN
48.0 was employed in these studies. First strand cDNA was
synthesised using Reverse-iT first-strand synthesis kits Superscript
III (Invitrogen). PCR was performed using gene-specific primers
(Supplementary Table 2) to confirm expression of PRKC-z-a. The
employed protocol comprised: initial cycle at 94 1C for 4min,
followed by 35 cycles consisting of denaturation at 94 1C for 20 s,
annealing at 57 1C for 30 s and extension at 72 1C for 1min. These
35 cycles were followed by 10 min of extension at 72 1C.
Assessment of PRKCI expression
As PRKCZ (chromosome 1) and PRKCI (chromosome 3) are
members of the family of atypical PK genes, and possibly
evolutionarily related, PCR reactions using gene-specific primers
(Supplementary Table 2) were performed to assess whether
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Figure 2 (A) Sequence of the antigenic peptide identified by poly-
clonal antiserum sc-216, provided by Santa Cruz. (B) Back translation
of the antigenic peptide to identify its location (bold italics) in the
30-terminal expressed sequence of exon 98 PRKCZ variant ‘a’ according
to the NCBI database (build 36, 2011). Upper-case letters signify
expressed sequence, whereas lower case letters are exonic but
untranslated. (C) Immunohistochemical detection of PKC-z-a protein in
(i) non-neoplastic, (ii) hyperplastic, (iii) prostatic carcinoma (Gleason
3þ 3) and (iv) prostatic carcinoma (Gleason 5þ 5). (D) Western blot of
PKC-z-a in human prostate cell lines. (E) Western blot data standardised
to b-actin expression. (F) PCR analysis of human prostate cell lines
confirming expression of PKC-z-a mRNA. (G) Relative levels of PKC-z-a
mRNA standardised to b-actin expression.
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PRKCI, potentially homologous with PRKCZ, was also transcribed
in the cell lines.
Transcriptome-walking
The known structure of the antigenic peptide sequence identified
by polyclonal antiserum sc-216 and its corresponding nucleotide-
coding sequence were employed as the starting point to investigate
the structure of the PRKCZ transcripts. mRNAs extracted from
PNT-2, LNCaP, DU145 and PC-3M cell lines as well as six primary
tissues (one benign and one malignant specimen from each of
three patients) were used as templates to generate corresponding
cDNAs. Oligonucleotide primer sequences (Supplementary
Table 2) were designed to the 30 end of PRKCZ (NM_002744),
beginning at the antigenic sequence with the aim of walking 50
upstream through the expressed sequence of the gene. Generic
primers (n-GTTC, where n¼A-, T-, C- or G-) together with a
series of unique target-specific primers (TSP1–9, Supplementary
Table 3) were employed to analyse gene expression in a series of
consecutive segments. Using cDNA synthesised from the expressed
mRNA’s, transcriptome-walking was performed using Seegene
(Rockville, MD, USA) DNA Speedup Premix Kit involving three-
step nested PCR reactions to generate specific products.
Three independent sets of transcriptome-walking experiments
were performed to interrogate transcribed sequence upstream of
exons 98–81, 81–39 and 39–1. Transcriptome-walking using
primers TSP1–TSP3 performed in the 50’30 direction from exon
98 and extending to exon 81 through the expressed message to
750 bp upstream of the epitope sequence identified transcription of
a non-coding region corresponding to variant ‘vq’. Transcriptome-
walking using TSP4–6 primers continued upstream by approxi-
mately 800 bp to exon 39. TSP7–TSP9 transcriptome-walking
proceeded an additional 450 bp upstream to the 30 end of exon 1.
The primers were designed to provide overlapping data and hence
confirm that each of the sequences retrieved was an extension of
the previous mRNA and not a new variant with a truncated 30 end.
The purified PCR product from each first-round amplification
(using TSP1, 4 or 7 plus universal upstream primers) was used as
the template for the second-round PCR amplification using TSP2,
5 or 8. The PCR products generated were employed as the
templates amplified in the third-round PCR using TSP3, 6 or 9
without further purification. All PCR reactions comprised heating
at 94 1C for 3min, then 35 cycles of 94 1C for 30 s, 62 1C for 30 s,
72 1C for 100 s and a final extension step of 72 1C for 7min.
Agarose electrophoresis was performed to identify the amplified
products (Supplementary Figure 1A–C). Bands excised from the
gels were submitted to nucleotide sequencing (Lark Technologies,
Takeley, UK). Derived sequences were subjected to BLAST and
ClustalW analysis to compare them with the PRKCZ gene sequence
within the NCBI database. Following analysis of the initial findings,
two additional sets of TSPs were designed to exons 46 and 25 to
confirm that the variants encoded by these exons were not
expressed in the ranges of interest.
To further characterise the expressed sequence corresponding to
variant ‘vq’, six additional TSPs (Supplementary Table 3) were
designed. TSPr1–TSPr3 were located within the non-coding region
of exon 89 ahead of the beginning of exon 90. TSPr4–TSPr6 were
designed within the novel sequence that had been identified 50
of exon 89 (Supplementary Figures 1D and E). Transcriptome-
walking with primers TSPr1–3 and TSPr4–6 continued beyond the
published sequence for variant ‘vq’. All bands were excised from
the gels, submitted to sequence analysis and a consensus sequence
compiled. To further elucidate the PRKCZ variant(s) expressed in
the specimens, a further round of transcriptome-walking was
performed, in triplicate, using TSP4–TSP6 designed to exon 81
(Supplementary Table 3). The primers were designed to provide an
overlap with the data obtained from TSPs1–3, and hence confirm
that the sequence retrieved was an extension of the previous
mRNA and not a new variant with a truncated 30 end. The
structure of all products was confirmed by sequence analysis.
RT–PCR confirmation of PRKZ variants expressed
A series of strategic RT–PCR reactions together with nucleotide
sequencing was performed using the data obtained from
transcriptome-walking and applied to the information available
within the contemporary NCBI database to confirm the transcrip-
tion of PRKCZ. Primer sequences were designed (Supplementary
Table 4; Figure 4A) using Primer 3 software (Whitehead Institute
for Biomedical Research, Cambridge, MA, USA; http://frodo.wi.mit.
edu/primer3/) to span known exon–exon interfaces, hence provid-
ing robust data with respect to encoded structures.
Region 1: To confirm the relationship between exon 87 (variant
‘m–u’) and exon 89 (variant ‘vq’) and to map the intervening
sequence that could not be charted by transcriptome-walking, a
common forward primer (Fwd-1a/b) designed to exon 81 was
paired with reverse primers located in the novel 50 extension of
exon 89 (Rev-1a) and in the 5
0 end of exon 89 (Rev-1b) previously
considered to be non-coding.
Region 2: To determine whether the intronic segment between
exon 87 and exon 89 was transcribed, a forward primer (Fwd-2)
was designed within the 30 end of exon 83 and paired with a reverse
primer (Rev-2) in the 50 end of exon 98.
Region 3: The objective of this part of the study was to analyse
the structure of the intronic region between exon 98 and exon 104
(the terminal sequence of variant ‘k’) and hence to obtain
structural information on the 13524 bp sequencing gap earlier
reported between the two terminal exons of variant ‘k’. Separate
forward primers (Fwd-3a and Fwd-3b) were designed within the
30 end of exon 98 and paired with a common reverse primer
(Rev-3a/b) located at the 5
0 end of exon 104. Alignment of
the resulting sequences was made to the consensus sequence
of PRKCZ within the contemporary NCBI database using BLAST
and ClustalW analysis.
Interrogation of NCBI database
To understand the location and distribution of the identified
sequences within the PRKCZ gene, alignments were made to the
contemporary published structure of the human chromosome 1
contig (Gregory et al, 2006; Levy et al, 2007). Sequences were
interrogated with respect to alignment, frequency of sequence
recurrence and the presence of any Alu sequences. Possible
locations of viral insertion sites, especially for viruses HPV and
XMRV, were also identified. Nucleotides #16–#370 correspond to
the terminal 30 UTR of exon 87 (variant ‘m–u’). Nucleotides #90–
#386 contain a region that simultaneously corresponds to Alu
sequences, viral insertion sites and a highly conserved marine
metagenome sequence.
Structure and expression of hypothecated protein
Although transcriptome-walking identified transcription of mRNA
corresponding to exon 83, including the 50 UTR and continuing
into the upstream genomic sequence, western blotting protein
extracts from prostate cell lines using polyclonal antiserum sc-216
revealed only a single band at 67.7 kD, corresponding to PKC-z-a
protein (Figure 2). No additional band was detected at 10.3 kD that
corresponded to variant ‘vq’. Although sequence analysis of the
transcriptome-walking products followed by strategic RT–PCR and
subsequent sequencing of those products confirmed expression of
the intact mRNA corresponding to exon 83, including its putative
coding region, the 50UTR and the adjacent short 50 intronic
segment, there was no evidence that any part of this message was
translated into the predicted protein.
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Analysis of the exonic structure of PRKCZ revealed the coding
sequence of the sc-216 epitope contained in exon 90 of PRKC-z-a to
be present also in exon 98 and included in variants ‘b’, ‘c’, ‘d’, ‘f ’,
‘g’, ‘h’, ‘I’, ‘j’, and ‘vm’ (Figure 1). To test the hypothesis that the
second mRNA sequence detected in the prostate cancer cells was
expressed as protein, a monoclonal antibody was generated against
the putative peptide obtained by back-translating the identified
mRNA sequence into protein followed by western blotting and
immunohistochemistry studies.
Generation of monoclonal antibody to the putative peptide
sequence
The hypothecated peptide sequence was analysed (http://gcat.
davidson.edu/rakarnik/kyte-doolittle.htm) to identify hydrophilic
domains (Kyte and Doolittle, 1982) as potentially suitable epitopes
to generate a monoclonal antibody (Foster, 1982; Bashir et al, 1998),
immunise Balb/c mice and perform a classical hybridisation with NS1
mouse myeloma cells (EuroGentech, Seraing, Belgium). A total of 13
hybridomas secreting monoclonal antibodies to the immunising peptide
and giving strong signals with clear distinction between benign and
malignant prostatic epithelium were cloned by limiting dilution.
Western blotting
Cell lines of different histogenic types were cultured to 80% confluence
in 175cm2 flasks. After detachment, cells were extracted by addition of
125ml of CelLytic M mammalian cell lysis reagent (Sigma-Aldrich,
Gillingham, UK) per 106 cells. After lysis and centrifugation at
12000 g for 15min to remove cell debris, each supernatant
containing solubilised proteins was collected and quantified using a
NanoDrop 1000 instrument.
For polyacrylamide gel electrophoretic separation, aliquots con-
taining 30mg total cell lysate protein were heated for 2min at 95 1C
and loaded above the separating gel (10% w/v) held in a Mini-Protean
3 Cell apparatus (Bio-Rad, Hercules, CA, USA). Proteins were
separated at an initial 80V until the samples had stacked and then
separated at 100V for 1h. Proteins were transferred to Hybond ECL
nitrocellulose membranes (Amersham Biosciences, Little Chalfont,
UK) using a Trans-alot electrophoretic transfer cell (Bio-Rad)
containing a transfer buffer (pH 8.3) comprising 25mM Tris-base,
192mM glycine and 20% methanol (v/v) at 100V (constant) for 1h.
Each blotted nitrocellulose membrane was placed in 10ml of 5% (v/v)
blocking solution (Geneflow, Fradley, UK) and incubated at
room temperature for 1h on a shaking platform. After draining,
each membrane was transferred to a solution of the primary antibody
(sc-216: diluted 1 : 1000 in TBST (20mM Tris, 500mM NaCl and
0.1% (w/v) Tween at pH 7.5) containing 5% (w/v) skimmed milk
powder or to 10ml of undiluted hybridoma 5A6 supernatant and
incubated overnight at 4 1C. Membranes were washed three times in
TBST for 10min, each time with constant agitation. Thereafter, 20ml
of rabbit polyclonal anti-(mouse immunoglobulin) conjugated with
horseradish peroxidase and diluted 1 : 10 000 in TBST was added and
incubated for 30min with constant agitation. After further washing
with TBST (for 10min, 15min and 30min, respectively) membranes
were rinsed three times with TBS for 15min each time before being
transferred to fresh ECL-Plus solution (Amersham BioSciences) and
incubated for 5min at room temperature. Membranes were exposed
to X-ray film (Hyperfilm, Amersham Biosciences) that was developed
and fixed in complete darkness.
RESULTS
Identification of PKC-z-a expression in primary prostate
cancers and prostate cancer cell lines
Immunohistochemistry using polyclonal antibody sc-216 that detected
a 20-mer peptide (Figure 2A) encoded within the 30-terminal domain
of PRKCZ (Figure 2B) confirmed strong expression of PKC-z-a by
prostate cancer cells but only very weak expression by non-malignant
prostatic epithelium (Figure 2C), including PNT-2 cells. Highest
expression was found in PC-3M cells, an observation supported
by western blotting and PCR (Figure 2D–G).
Transcriptome-walking to confirm PRKCZ variants
expressed in prostate cancers and prostate cancer cell lines
Transcriptome-walking in the 50’30 direction beginning with a
primer sequence in PRKCZ exon 98 complementary to that
encoding the peptide epitope recognised by antibody sc-216,
primers TSP1–TSP3 detected strong signals from PRKCZ exons
98–81 (Figure 2) in all cell lines and tissue specimens and
identified transcription of the regions encoding exons 98, 90, 86,
85, 84, 82 and 81. Primers TSP4–TSP6 identified transcription of
exons 77, 72, 69 and 55. Primers TSP7–TSP9 identified transcrip-
tion of exons 51, 43, 39, 9, 8, 6 and the 30-terminal sequence of
exon 1. Sequence analysis of the amplified products confirmed
alignment to variant ‘a’ PRKCZ. In addition, generic primer
C-GTTC identified products corresponding PRKCZ variant ‘vq’
(exon 89) together with a contiguous 253 bp extension into the
adjacent upstream intron (Figure 1B) in cell lines DU145, PC-3M
and in the three primary prostatic carcinomas but not in PNT-2,
LNCaP or in the benign tissues (Supplementary Figure 1A–E).
Control experiments confirmed each of the extracted mRNAs
employed as template for transcriptome-walking and subsequent
expression studies to be free from contamination by genomic DNA
(Supplementary Figure 1F). Interrogation of the NCBI database
revealed this 253 bp sequence to match that defined by GenBank
Accession: AA280988. A consensus structure for the upstream
intronic extension of exon 89 was generated from the different
PCR products (Figure 3). Expression of variant ‘vq’ and its
upstream intronic extension sequence was confirmed by RT–PCR
and detected only in the malignant prostatic cell lines and primary
tumour tissues but not in PNT-2, LNCaP cells or in benign tissues.
Further transcriptome-walking and nucleotide sequence analysis
confirmed expression of the entire length of PRKCZ variant ‘a’.
RT–PCR confirmation of PRKCZ variants expressed
Transcription of the PRKCZ genome immediately upstream and
downstream of exon 89 was analysed by PCR (Figure 4A,
Supplementary Table 4). These findings supported the transcrip-
tome-walking data with a sequence identity of 93.2% and
confirmed variant of PRKCZ (designated PRKC-z-PrC) to be
transcribed in prostatic carcinoma PC-3M cells (Figure 4B-E).
Quantitative PCR analysis of mRNA extracted from prostatic
epithelial cell lines identified the relative expression of mRNA for
PRKC-z variants ‘a’ and ‘PrC’ (Figure 5A). Comparison of the
expression levels of these variants in parental PC-3M cells and
their corresponding knockdown derivative cells, si-PRKC-z-PC3–
MT1–6, revealed expression of PRKC-z-a to be significantly reduced,
whereas variant PRKC-z-PrC remained unaltered (Figure 5B),
suggesting expression of these two variants to be differentially
regulated. PRKC-i (the other member of the group of atypical
PKC’s and having partial homology to PRKC-z) was not detected in
PNT-2 cells or in the non-malignant tissues from one of the two
additional prostate specimens (Figure 5C). Quantitative PCR
analysis confirmed relatively low levels of PRKC-i in PNT-2,
LNCaP and PC-3M cell lines but high levels expressed in DU145
cells (Figure 5D).
Independent confirmation of PKC-z-PrC expression in fresh
prostatic tissues
The ‘Check 20 primer set (Supplementary Table 4), used to amplify
the novel expressed sequence, identified anB1 kb band present in
mRNA from PC-3M cells and the malignant components of three
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10        20        30        40        50        60        70        80      90       100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
PC-3M cells AGGGGGGGGGTCACCCTTTTGGTCNGGGTTCAAGAACNTCCATGAGAACGGCTTGTTAAGCCAGTTANTTGTCGGTGCCCCTNTGAACAAGGACCCCCCC
Case #4667T GGGGNAGGTTCTANCNTTTTGGTCNGGGTTCNAGAACGTC-ATGAGAACGGCTTGTTCAGCCAGTTAGTTGTCGGTGCCCCTCTGAACAAGGACCCCCCC
Case #4327T AGGGGGGGGGTCCNCCTTTNGGTNNGGGTTCNAGAACNTC-ATGAGNACGGCTTGTTAAGCCANTTANTTGTCGGTNCCCCTNTNAACAAGGACCCCCCC
----------------------------------------------------------------------------------------------------
110       120       130       140       150       160       170       180       190       200 
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
PC-3M cells AAGGAAGGGGGTGGCCTCNCATGGGTGGCTGGGGATCCTGCTCCGTCCCACATGTGGCCAGCATGGCCNACACTGGCATTTNTNAGCTCGACAACAATTT
Case #4667T AAGGAAGGGGGTGGCCTCGCATGGGTGGCTGGGGACCCTGCTCCGTCCCACATGTGGCCAGCATGGCCGACACTGGCATTTCTCAGCTCGACAACAATTT
Case #4327T AAGGAAGGGGGNGGCCTCCCATGGGTGGCTGGGGATCCTGCTCCGTCCCACATGTGGCCAGCATGGCCNACACTGGCNTTTNTAANCTCGACAACAATTT
----------------------------------------------------------------------------------------------------
210       220       230       240       250       260       270       280       290       300 
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
PC-3M cells TTCTGACTTTGGATATTTTCTANATTTTGNGTTGNAANAAAAAACACTTGGCANTCAAATNCTAGGCANATTGAAATGCTGACTTTCTCACTGTTTCATT
Case #4667T TTCTGACTTTGGATATTTTCTAGATTTTGTGTTGTAAGAAAAAACACTTGGCAGTCAAATACTAGGCAGATTGAAATGCTGACTTTCTCACTGTTTCATT
Case #4327T TTCTGACTTTGGATATTTTCNANATTTTGNGTTGNAANAAAAAACACTTGGCANTCAAATNCTAGGCANATTGAAATGCTGNCTTTCTCACTGTTTCATT
Exon 89/104 --------------------------------TGTAAGAAAAAACACTTGGCAGTCAAATACTAGGCAGATTGAAATGCTGACTTTCTCACTGTTTCATT
310       320       330       340       350       360       370       380       390       400 
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
PC-3M cells TTGNGATTGAANTGCGTGCAAACNCTCAATCAA
Case #4667T TTGTGATTGAAGTGCGTGCAAACACTCAATCAA
Case #4327T TTGNGATTNAAGTGCNTGCAAACNCTCAATCAA
Exon #89/104 TTGTGATTGAAGTGCGTGCAAAA---CACTCAATCTGGTAGGGATGATGCCCGCGCGGAGCTGACCCTTCTCCTATTGTTTTTCCAAGCTGGAGAAGAAG
410       420       430       440       450       460       470       480       490       500 
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
PC-3M cells
Case #4667T
Case #4327T
Exon 89/104 CAGGCGCTCCCTCCATTCCAGCCACAGATCACAGACGACTACGGTCTGGACAACTTTGACACACAGTTCACCAGCGAGCCCGTGCAGCTGACCCCAGACG
510       520       530       540       550       560       570       580       590       600 
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
PC-3M cells
Case #4667T
Case #4327T
Exon 89/104 ATGAGGATGCCATAAAGAGGATCGACCAGTCAGAGTTCGAAGGCTTTGAGTATATCAACCCATTATTGCTGTCCACCGAGGAGTCGGTGTGAGGCCGCGT
Figure 3 Consensus sequences derived from three replicates for each specimen obtained by genome walking in a 50’30 direction from exon 98 comparing
expression sequence data from cell line PC-3M with that from primary carcinomas #4667T and #4327T and their alignment with the published sequence for exon 89
(variant ‘vq’). The sequence originating at nucleotide #223 corresponds to the start of the 50 UTR of exon 89 with the obtained sequence 1–222 located within the
upstream intronic sequence. Data obtained from the other cell lines and prostate cancer specimens revealed similar matching sequences and alignments (data not shown).
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Figure 4 PCR amplification of mRNA from PC-3M cells. (A) Schematic diagram of the three contiguous regions, including intronic sequences, identified
by genome walking to be expressed in prostate cancer cells. Red and green rectangles identify the positions of forward and reverse PCR primers,
respectively (Supplementary Table 4). (B) Control gel confirming absence of contaminating genomic DNA. (C) Region 1: Three products atB700,B1400
andB1600 bp obtained using primer pairs 1A/B spanning exon 87 to the 50 extension of exon 89 within the intervening intronic sequence. (D) Region 2:
Single product at B600 bp spanning exons 89–98 including intervening intronic 223 bp. (E) Region 3: Single product of B594 bp from primer pair 3A
spanning exons 98–104, including intronic 288 bp. A smaller product at B554 bp (data not shown) was derived from primer pair 3B.
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fresh radical prostatectomy specimens but not in the non-
malignant tissues (Figure 6A and B). The amplified sequence
extended from the 30-terminal region of variant m–u (exon 87)
through the intervening exonised intronic region to the 50
extension of variant ‘vq’ (exon 89). Sequencing analysis confirmed
identity between this region expressed in the PC-3M cells and that
detected in the primary malignant tissues (Figure 6C).
Generation of monoclonal antibody to the putative peptide
sequence
Translation of the novel transcribed sequence (Figure 7A) with
run-through of stop codons (Williams et al, 2004) identified a
putative peptide 985 amino acids long (Figure 7B). Four in-frame
candidates were considered as potential antigenic sites to raise
monoclonal antibodies to this hypothecated protein. Protein
BLAST confirmed peptide sequence – RDRPLRRDRRGKRQR –
(identified in red) to be unique to PRKCZ. Hydropathy analysis
(Kyte and Doolittle, 1982) showed this sequence and to exhibit the
lowest hydrophobicity (Figure 7C). Conformation modelling
revealed the sequence to be optimally expressed by the intact
folded protein. This peptide was employed as the immunogen to
generate monoclonal antibodies. Clone 5A6 was selected for
further analysis because of its relative strength, lack of non-
specific background staining and its discrimination between
benign and malignant prostatic epithelium.
Expression of protein identified by 5A6 in epithelial cell
lines and prostatic tissues
Western blotting using hybridoma supernatant 5A6 revealed a
single strong band at 96 kD in the malignant prostatic epithelial
cell lines PC-3M, DU145 and LNCaP but not in the benign PNT-2
cells (Figure 7D). The 96 kD immunoreactive band was not
detected in proteins extracted from non-malignant lung cell line
(Beas-2b) or from four malignant cell lines including lung (COR-
L88), bladder (HT1197), pancreas (PANC) and breast (MCF-7).
The ‘PrC’ and ‘a’ variants were differentially identified as distinct
bands by monoclonal antibody 5A6 and conventional polyclonal
antiserum sc-216, respectively (Figure 7E). Tissue sections from
begin and malignant prostatic tissues stained using monoclonal
antibody 5A6 revealed strong staining of malignant prostatic
epithelial cells in contrast to an absence of staining non-malignant
prostatic epithelium (Figure 7F).
Interrogation of putative protein structure
NCBI protein Blast of the putative protein from the novel transcribed
sequence (Figure 7B) revealed amino acids 21–101 to correspond with
the hypothetical protein encoded by LOC 100507445, amino acids
607–694 corresponded to the catalytic domain of atypical PRKC–i,
whereas amino acids 624–691 corresponded to the catalytic domain
of PRKC–b. Although no other structural similarities or motifs were
identified, potentially, this novel protein could exhibit kinase activity
that is not under normal regulatory control.
Interrogation of human genome
Alignment of all amplified sequences to human genome contig
GRCh37.p2 (Gregory et al, 2006) identified a continuous expressed
sequence 3060 bp long (Supplementary Figure 2) within the PRKCZ
gene having 96% identity with 33 gaps. The compiled sequence
extended from the 30-terminal region of exon 81 to the 50 end of
exon 94, providing novel data completing intervening sequencing
gaps and confirming transcription of the included intronic
segments. The corresponding coordinates on the contig were
identified as 1592941–1595972. Nucleotide BLAST revealed this
expressed sequence to be replicated at three additional sites within
0
100
200
300
400
R
el
at
iv
e 
ex
pr
es
sio
n
m
R
N
A
PC
-3M
DU
14
5
LN
Ca
P
PN
T-2
Cell lines
#4
66
7T
#4
66
7N
#4
32
7T
#4
32
7N
PC
-3M
DU
14
5
LN
Ca
P
PN
T-2
-
RT
-
PC
R
-Actin
PRKC-
0
8
12
R
el
at
iv
e 
fo
ld
PR
KC
- 
m
R
N
A
PC
-3M
Du
14
5
LN
Ca
P
PN
T-2
10
6
4
2
Cell lines
0
100
200
300
400
R
el
at
iv
e 
ex
pr
es
sio
n
m
R
N
A
PC
-3M
PN
T-2
Cell lines
si-
PR
KC
--
PC
-3M
T1
-6
Figure 5 Expression of genes PRKC-z and PRKC-i in prostate epithelial cells. (A) Real-time PCR analysis of PRKC-z variants ‘a’ (white bars) and ‘PrC’ (dark
bars) in prostate cell lines using the DDCT method. (B) Expression of variants ‘a’ (white bars) and ‘PrC’ (dark bars) in the parental PC-3M cells and their
knockdown derivative si-PRKC-z-PC-3MT1-6 cells relative to that in PNT-2 cells (C) 1% (w/v) agarose gel electrophoresis of PRKC-i (top) and b-actin
(bottom) in malignant and non-malignant prostate cancer cell lines and tissues Amplification cycle number was 40 for Real-time PCR or 35 for RT-PCR.
–RT (Reverse transcriptase not included) and –cDNA (template not included) represent negative controls. (D) Expression of PRKC-i quantified in prostate
epithelial cells.
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the human genome: on the negative strand of chromosome 1p in
the open reading frame C1orf86 (NM_001146310, coordinates
2135481–2103093), in locus LOC100506504 (XM_003120338)
adjacent to C1orf86 on the negative strand of 1p36 and on the
positive strand of chromosome Xq23 (NT 011651.17) with 98%
identity. Interrogation of expressed sequence from 1 kb above (50)
the start of the compiled sequence (position 1590926) to the end
(30) of the sequence (position 1594986) revealed the presence of a
single Alu block 285 bp long beginning at nucleotide #90 of the
compiled sequence and located within the 30-terminal domain of
exon 87 (variant ‘m–u’, Figure 4). This region also contained a
potential insertion site for viruses HPV and XMRV, although
neither was identified in these PC-3M cells (data not included).
DISCUSSION
This study has identified a previously unreported transcript
(designated PRKC-z-PrC) expressed in prostate cancer cell lines
and tissues within the 30 region of human gene PRKCZ.
Transcriptome-walking together with targeted PCR analysis and
subsequent oligonucleotide sequencing studies performed in
....|....|... |....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
tgggctagagaacga caagggaat agagagagtgggttagagagtg gtgagccagtgaatgagtgagtgagcaggagtgggttagagagcgagggag
---GCTA-------------------------------------------------------TGANTGAGTGAGCANGAGTGGGTTAGAGAGCGAGG AG
3510 3520 3530 3540 3550 3560 3570 3580 3590 3600....|....|....|....|....|... |....|....|....|....|....|....|.. .|....|....|....|....|....|....|....|
tgagtgaatgagtgggctaaagagggccgggcgcggtgg tcacgcctgtaatcccagcactttgggaggccgaggagggcagatgatctgaggtcagca
TGAGTGAATGAGTGGGCTAAAGAGGGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGAGGGCAGATGATCTGAGGTCAGCA
3610 3620 3630 3640 3650 3660 3670 3680 3690 3700....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
gttcgggagcagcctggtcaacatggtgaaaccctgcctctactaaaaatacaaaaacaaaattagccaggcgtggtggcgggcgcctgtactcccagct
GTTCGGGAGCAGCCTGGTCAACATGGTGAAACCCTGCCTCTACTAAAAATACAAAAACAAAATTAGCCAGGCGTGGTGGCGGGCGCCTGTACTCCCAGCT
3710 3720 3730 3740 3750 3760 3770 3780 3790 3800....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
actcagaaggctgaggcgggagaatggtgtgaacctgggaggtggagcttgcagtgagccgagatcgtgccactgcacttcagcctgggagacagagcga
ACTCAGAAGGCTGAGGCGGGAGAATGGTGTGAACCTGGGAGGTGGAGCTTGCAGTGAGCCGAGATCGTGCCACTGCACTTCAGCCTGGGAGACAGAGCGA
3810 3820 3830 3840 3850 3860 3870 3880 3890 3900....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
gtctcaaaacaaaaacaaaaaacaaaattagctgggcatggtggtgcatgcctgtagtcccggctactcaggagactgaggcaggagaatagcttgaatc
CT CAAAACAAAAACAAAAAACAAAATTAGCTGGGCATGGTGGTGCATGCCTGTAGTCCCGGCTACTCAGGAGACTGAGGCAGGAGAATAGCTTGAATC
3910 3920 3930 3940 3950 3960 3970 3980 3990 4000....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
ggagtcagaggttgcagtgagccgagatcgcgccactgcactccagcctgggcaacagagcaagactccatctcaaaaaaaaagtgggctagagagtgag
GGAGTCAGAGGTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCAACAGAGCAAGACTCCATCTCAAAAAAAAAGTGGGCTAGAGAGTGAG
4010 4020 4030 4040 4050 4060 4070 4080 4090 4100....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
tgagtgaatgagtgaatgggagtgggttagcgagggagt agagggtgaatgggagtgggttagagagggagtgagagggtgaatgggagtgggttagag
TGAGTGAATGAGTGAATGGGAGTGGGTTAGCGAGGGAGTGAGAGGGTGAATGGGAGTGGGTTAGAGAGGGAGTGAGAGGGTGAATGGGAGTGGGTTAGAG
4110 4120 4130 4140 4150 4160 4170 4180 4190 4200....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
agtgagggagtaagcgagtgaatgtctcttggtgctgctgtaacagaatacctgagcgagcctgggtaatttctagggagcagagttctttcccagctgt
AGTGAGGGAGTAAGCGAGTGAATGTCTCTTGGTGCTGCTGTAACAGAATACCTGAGCGAGCCTGGGTAATTTCTAGGGAGCAGAGTTCTTTCCCAGCTGT
4210 4220 4230 4240 4250 4260 4270 4280 4290 4300....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
ggaggttgggagtccagggtcatggtgccagcaggcttggtgtctggtgaggcctgatctctgcttccaagatggcgcccaaacactgcattccccggag
GGAGGTTGGGAGTCCAGGGTCATGGTGCCA CAGGCTTGGTGTCTGGTGAGGCCTGATCTCTGCTTCCAAGATGGCGCCCAAACACTGCATTCCCCGGAG
4310 4320 4330 4340 4350 4360 4370 4380 4390 4400....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
gagagaggggaggaaggccacgtgtccacatggcagaaggcagagaggaatccatgcccaagctgtcttgacagctacaggagtttgtctgtgagggcgg
GAGAGAGGGGAGGAAGGCCACGTGTCCACATGGCAGAAGGCAGAGANGAATCC-----------------------------------------------
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Figure 6 Confirmation of novel sequence expression in prostatic carcinomas. (A) Tissue morphology of primary prostatic tissues (i) Primary prostatic
carcinoma (#29110T), (ii) predominantly benign prostatic tissue (#31105T) but containing small clusters of carcinoma cells infiltrating between the benign
glands. (B) Amplification of novel sequence using Check 2 primer set (Supplementary Table 4) in PC-3M cells (top) and in three primary prostatic tissues
(middle). Abbreviations: B¼ predominantly benign tissue; T¼ tumour tissue. Contamination of benign tissue by prostate cancer cells revealed as a weak
band in the benign lane (#31105B). (C) Nucleotide sequence of the products from the gels illustrated in panel B aligned with the consensus sequence.
Yellow arrows indicate location of the Check 2 primer pair.
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prostate cancer cell line PC-3M cells confirmed simultaneous
transcription of PRKCZ variant ‘a’ (PRKC-z-a) together with that of
novel sequence PRKC-z-PrC. Both sequences are translated into
distinct proteins (PKC-z-a and PKC-z-PrC, respectively) in prostate
cancer cell lines and in primary prostatic carcinomas but not in
benign prostatic epithelia or in non-prostatic epithelial cell lines.
Western blotting and immunohistochemistry using monoclonal
antibody 5A6 raised to the hypothecated peptide encoded by the
novel sequence revealed protein PKC-z-PrC to be expressed only by
prostate cancer cells. The novel expressed gene sequence extends
between PRKCZ exons 88 and 104 over a distance in excess of
3060 bp including intervening introns and sequences previously
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Figure 7 Analysis of novel peptide epitope expression. (A) Transcript sequence obtained from the 30-UTR of exon 98 amplified as part of Region 2
(Figure 4). The sequence encoding the epitope peptide (below) is shown in red. (B) Translation of DNA consensus sequence to a hypothetical peptide.
The subsequent immunising epitope sequence used as immunogen selected by hydropathy analysis is indicated in red. (C) Kyte and Doolittle hydropathy
analysis of hypothecated peptide indicating (arrows) the hydrophilic immunogenic region. (D) Western blot of human epithelial cell lines using monoclonal
antibody 5A6. Cell lines: PNT-2: non-malignant prostate; PC-3M, LNCaP, Du145: malignant prostate; . Beas 2b, COR-L88: malignant lung; HT1197:
malignant bladder; PANC: malignant pancreas; MCF-7: malignant breast). (E) Western blot comparing the relative motilities of the bands identified in benign
(PNT-2) and malignant (PC-3M) prostatic epithelial cell lines using monoclonal antibody 5A6 (variant ‘PrC’) and polyclonal antiserum sc-216 (variant ‘a’).
(F) Immunohistochemistry of human prostate tissues using monoclonal antibody 5A6: (i) benign epithelium (ii) malignant epithelium.
PKC-zeta variant selectively expressed in prostate cancer
S Yao et al
396
British Journal of Cancer (2012) 107(2), 388 – 399 & 2012 Cancer Research UK
G
e
n
e
tic
s
a
n
d
G
e
n
o
m
ic
s
considered as non-coding. Interrogation of contig GRCh37.p2
(Gregory et al, 2006) revealed a block of Alu sequences (Alu-Sx,
Alu-Sb, Alu-Sq, Alu-Sb1, Alu-Sc, Alu-Sp, Alu-Sj, Alu-Sb2) 285 bp
long close to the origin of the novel sequence. Translation of the
expressed sequence with run-through of the contained stop codons
(Williams et al, 2004) identified a potential protein 985 amino
acids long that contained a single region corresponding to the
catalytic domains of classic PRKC–b and atypical PRKC–i enzymes
but no other functional homologies or motifs. PCR analysis of
mRNA extracted from fresh primary prostatic tissues supported
the proposition that PRKC-z-PrC is expressed only in malignant
prostatic epithelium. The finding that PRKC-z-a and PRKC-z-PrC are
expressed simultaneously together with the observation that RNAi
directed at PRKC-z-a failed to reduce expression of PRKC-z-PrC
supports a mechanism whereby these alternative sites, possibly
pseudogenes (Vanin, 1985; Andrea and Walsh, 1995), potentially
allow simultaneous expression of the two distinct variants,
possibly from identical genomic sequences that are located
separately within the genome. There is documented support for
the proposal that alternative PKC-z transcripts can be transcribed
simultaneously from a common PRKCZ gene sequence in the
absence of gene duplication or existence of a structurally identical
pseudogene (Marshall et al, 2000). Although there is no evidence
that PRKCZ is oncogenic, anomalous expression of PRKCZ variant
PKC-z-PrC exhibiting alternative (that is, PKC-b or PKC-i) kinase
activity may promote the aggressive phenotype of prostate cancer.
In contrast to some human malignancies, prostate cancer may
be associated with multiple gene loci each independently
conferring a low but cumulative risk (Al Olama et al, 2009; Eeles
et al, 2009). Genetic susceptibility to prostate cancer is complex,
possibly caused by interaction of low-penetrance genes that
include rare putative autosomal dominants (0.003–0.06 allele
frequency). Linkage analysis has identified susceptibility with loci
on chromosome 1p36 (Gibbs et al, 1999; Xu et al, 2001),
particularly the CAPB (carcinoma prostate brain) locus
(Badzioch et al, 2000). However, the effect of CAPB appears to
be independent of the HPC1 locus (1q24-25) that has been
confirmed in families with aggressive prostate cancer occurring at
median age. Furthermore, very low levels of allelic imbalance
found at HPC1 and 1p36 make it unlikely that these loci contain
classic tumour suppressor genes (Ahman et al, 2000). Nevertheless,
human chromosome 1p36 is recognised to be a fragile region, as
evidenced by the Alu blocks identified in this study. The frequent
structural changes occurring in this region, particularly deletions
(Battaglia and Shaffer, 2008), are associated with many different
mesenchymal and epithelial malignancies. Decreased expression of
TERE1 that maps at 1p36.11–36.33 occurs in some 61% of aggres-
sive prostate cancers, particularly metastases (McGarvey et al, 2003).
TERE1 is closely linked to DISP3 (1p36.22) that encodes multi-span
transmembrane proteins implicated in the processing of lipid-
enhanced secreted proteins (Katoh and Katoh, 2005), a process we
have reported to be functionally implicated in aggressive prostate
cancer (Forootan et al, 2009). Within the 1p36 locus, p73 encodes a
protein with a high level of homology to p53 that is infrequently
sporadically uninhibited. Although germ-line mutations within
p73 do not predispose to prostate cancer (Peters et al, 2001) and
expression of p73 is not modulated in prostate cancer PC-3M cells
when PRKC-z (at 1p36.33) is knocked down following RNAi
(Yao et al, 2010), it is possible that p73 may substitute for some
p53 activities when that gene is mutated in B3–42% of prostate
cancers (Agell et al, 2008), thus promoting the aggressive
phenotype. Similarly, expression of TNFR2 (also encoded
at 1p36.2) is deleted or mutated in a range of human malignancies
but not modulated in PC-3M cells following PRKC-z knockdown.
Structural aberrations (deletions, tandem duplications,
translocations, insertions and inversions) within the genome
of malignant cells are frequent (Beerenwinkel et al, 2007;
Bignell et al, 2010).
PKCs comprise a large family of enzymes that mediate multiple
functions including maintenance of internal homoeostasis,
response to external stimuli and modulation of cellular phenotype.
This family of enzymes, defined by conserved sequences within
their catalytic domains (Hanks et al, 1988) is a large, hetero-
geneous and continually evolving group with origins extending to
the most primitive unicellular organisms (Mellor and Parker, 1998;
Manning et al, 2002). Within the PKC super family, atypical PKCs
(l/i and z) are structurally and functionally divergent from other
members (Schmitz and Heinisch, 2003). These are powerful
regulatory enzymes that control the polarity and migration of
individual cells as well as the development of multi-cellular
structures, (Suzuki et al, 2003) frequently mediating opposing
effects on homoeostatic regulators and mechanisms such as ion
channels (Muscella et al, 2005). The spectrum of putative PK genes
has been augmented following identification of individual PK gene
duplication, pseudogenes and genes encoding truncated enzymes
(Standaert et al, 2001), emphasising that the family of PKC genes
and corresponding proteins is not only continually evolving but is
constantly diversifying with respect to the functions of individual
members. Genetically, the presence of Alu sequences in an open-
reading frame, such as those identified in this study, produce
genetic instability, usually altering gene expression or causing
disruption by insertional mutation (Batzer and Deininger, 2002)
resulting in homologous recombination leading to generation of a
new genetic variant. Genomic analyses have revealed structural
alterations in the subtelomeric region of human chromosome 1p to
be associated with several different malignancies and to harbour
a novel tumour suppressor (Bagchi and Mills, 2008). This region
(chromosome 1p36) is not only under intense evolutionary pressure
(van der Drift et al, 1999) but is an important region of phylogenetic
divergence separating Homo sapiens from members of the Pongidae
(Conte et al, 1999) and other ape species (Weise et al, 2005).
Therefore, it is not surprising that this relatively unstable region of
the human genome is also involved in promoting the malignant
phenotype as well as contributing to evolutionary divergence,
possibly employing similar mechanisms (Krull et al, 2007).
The specific mechanism(s) by which PKC-z promotes invasion
and metastasis of human prostate cancer are not yet elucidated,
although the gene is recognised to be pleiotropic. Discovery of
gene splice variants has revealed that one gene may potentially
produce multiple different isoforms emphasising the complexity of
their involvement in the spectrum of cellular activities. Variant
RNA transcripts generated by alternative splicing (Brett et al, 2002;
Modrek and Lee, 2002), possibly directed by Alu sequences (Krull
et al, 2005; Corvelo and Eyras, 2008; Gal-Mark et al, 2008;
Romanish et al, 2009) or by ‘read-through’ of intronic sequences
(Kaer et al, 2011) may be translated into proteins containing (or
omitting) alternative motifs, binding sites and subcellular localisa-
tion signals. With respect to PK, isoform PKM-z containing a novel
PKC-z catalytic domain has been reported as specific to the brain
(Hernandez et al, 2003) and PKC-zII, another newly identified
member of the PKC-z family, is a truncated form of the protein
actively involved in cell polarity through inhibition of tight
junction formation (Parkinson et al, 2004). Retention of intronic
sequences and subsequent generation of novel products exhibiting
biological activities out-with the recognised function of specific
genes is a powerful driver of phenotypic diversity within malignant
cells (De Rosa et al, 2007) as well as in normal cellular evolution
(Calvanese et al, 2008; Gontijo et al, 2011). Inclusion of catalytic
domains characteristically expressed in classic PKC-b and atypical
PKC-i- enzymes provides novel evidence that anomalous variants
of PK enzymes are powerful agents potentially able to indepen-
dently modulate the malignant prostatic phenotype out-with
normal regulatory mechanisms. Our current studies emphasise
the importance of independently characterising all gene sequences
transcribed in each individual cancer as expression of particular
gene variants may significantly modify the malignant phenotype,
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particularly the biological behaviour of individual malignancies,
with profound implications for their appropriate management and
clinical outcome.
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